Sangamo Therapeutics Inc - Company Profile

Powered by

All the data and insights you need on Sangamo Therapeutics Inc in one report.

  • Save hours of research time and resources with
    our up-to-date Sangamo Therapeutics Inc Strategy Report

  • Understand Sangamo Therapeutics Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Sangamo Therapeutics Inc: Premium Databases

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Sangamo Therapeutics Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

A sample of Sangamo Therapeutics Regulatory Milestones data

Drug Name Generic Name Brand Name Company Name Expiry Geography Constraining Patent Number Constraining Patent Expiry Drug Expiry (Estimated) Highest Development Stage
Showing 3 of 9 results.
Deserunt mollit sunt Lorem Lorem Lorem Pfizer Inc Lorem WXYZ Lorem Pending Lorem
TX-200 - - Sangamo Therapeutics Inc United States US2020283529 - Pending -
SB-FIX - - Sangamo Therapeutics Inc Japan JP6535684 Dec-2034 - -
SB-FIX - - Sangamo Therapeutics Inc United States US9771403 Dec-2034 - Inactive

A sample of Sangamo Therapeutics Inc Review Designation data

Drug Name Generic Name Company Name Indication Geography Designation Type Designation Status Designation Date
Showing 3 of 9 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore Lorem Pfizer Inc Lorem Lorem Lorem Lorem 09 Jan 2020
giroctocogene fitelparvovec giroctocogene fitelparvovec Sangamo Therapeutics Inc Hemophilia A (Factor VIII Deficiency) EU Orphan Drug Designation Designated 22 May 2017
giroctocogene fitelparvovec giroctocogene fitelparvovec Sangamo Therapeutics Inc Hemophilia A (Factor VIII Deficiency) United States Fast Track Designation Designated 16 May 2017
giroctocogene fitelparvovec giroctocogene fitelparvovec Sangamo Therapeutics Inc Hemophilia A (Factor VIII Deficiency) United States Orphan Drug Designation Designated 03 May 2017
Regulatory Milestones

Feature

Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

Benefit

Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.

The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.

US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).

Value

Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .

Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.

Premium databases is part of our industry range of products

Gain a 360-degree view of Sangamo Therapeutics Inc and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer